The latest cohort of companies have joined the Venture Lab acceleration programme for early-stage companies, created by non-profit foundation the BioInnovation Institute (BII). Designed to help build research-based ideas with high-growth commercial potential into viable start-ups, BII’s 12-month Venture Lab programme supports business acceleration, scientific and team development. It provides… Read More
News round-up for 21-25 August by DDW Editor Reece Armstrong A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Covid researchers launch Monkeypox study A new study investigating a potential treatment… Read More
A new start-up has launched with an aim of developing therapeutics that address synaptic dysfunction in patients suffering from central nervous system (CNS) disorders. Gate Neurosciences was founded in 2019 by a team of neuroscientists with the goal of addressing the urgent need for more effective treatments… Read More
Three international life sciences start-ups have received investment from the BioInnovation Institute (BII). The three new ventures were chosen as part of the BII’s focus on developing scientific initiatives across the therapeutics and health tech space. The companies, Sevenless Therapeutics, VEIL.AI and Myopax, will receive… Read More
Listen to this article on the DDW Podcast: From AI to 3D deep-learning research to biologics, Lu Rahman selects some interesting global start-ups pushing the boundaries in drug discovery. Owkin French-American startup, Owkin is focussed on using artificial intelligence (AI) to discover and develop better treatments for… Read More
A drug candidate for heart attacks which contains venom from a deadly spider has moved closer to clinical trials due to investment of $23 million. A research team at the University of Queensland have developed a potential therapy for heart attacks and stroke which uses a molecule… Read More
Félix Lavoie-Pérusse is co-founder and Chief Commercial Officer of Saguaro Technologies. He tells Lu Rahman why the company wants to make drug discovery more successful with its next-generation technologies in cell culture. Saguaro partners with drug discovery scientists to convert potentially disruptive technologies into valuable cell culture products. These… Read More
